Worldwide Healthcare Trust PLC Edison issues review on Worldwide Healthcare Trust
18 5월 2016 - 12:10AM
RNS Non-Regulatory
TIDMWWH
Worldwide Healthcare Trust PLC
17 May 2016
London, UK, 17 May 2016
Edison issues research review on Worldwide Healthcare Trust
Worldwide Healthcare Trust (WWH) has a track record of more than
20 years investing in the healthcare sector. A change to its
mandate six years ago has seen it expand its remit from
pharmaceuticals and biotechnology to the whole healthcare sector.
While the core of the portfolio is invested in US stocks, WWH is
differentiated from the majority of peers by its c 15% weighting in
emerging markets. The trust has substantially outperformed its
benchmarks over three, five and 10 years and benefits from the
stable management of manager Sam Isaly, a founding partner of
specialist healthcare investment manager OrbiMed. The discount to
NAV of c 7% is wider than long-term averages, suggesting potential
to narrow from here.
At 16 May, WWH's shares were trading at a 7.3% discount to
cum-income net asset value. This is a little wider than the target
maximum discount of 6%, and also wider than the one-, three- and
five-year averages (5.3%, 4.2% and 5.6% respectively). Given the
historical support from share buybacks (c 457k shares bought back
so far in 2016 at a cost of GBP7.9m), it is reasonable to expect
the discount will narrow towards the long-term average, although in
the run-up to the US presidential election, appetite for healthcare
investments may remain subdued.
Click here to view the full report.
All reports published by Edison are available to download free
of charge from its website: www.edisoninvestmentresearch.com
About Edison: Edison is an international equity research firm
with a team of over 110 analysts, investment and roadshow
professionals and works with both large and smaller capitalised
companies, blue chip institutional investors, wealth managers,
private equity and corporate finance houses to support their
capital markets activity. Edison provides services to more than 420
retained corporate and investor clients from offices in London, New
York, Frankfurt, Sydney and Wellington. Edison is authorised and
regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide
investment advice. Edison's reports are not solicitations to buy or
sell any securities.
Contact details: Learn more at www.edisongroup.com and connect
with Edison on:
LinkedIn www.linkedin.com/company/edison-investment-research
--------- ----------------------------------------------------
Twitter www.twitter.com/Edison_Inv_Res
--------- ----------------------------------------------------
YouTube www.youtube.com/edisonitv
--------- ----------------------------------------------------
Google+ https://plus.google.com/105425025202328783163/posts
--------- ----------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAARMATMBMBBLF
(END) Dow Jones Newswires
May 17, 2016 11:10 ET (15:10 GMT)
Finsbury Worldwide Pharm (LSE:FWP)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Finsbury Worldwide Pharm (LSE:FWP)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
